Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search:
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
dewey-ones:"140 - Specific philosophical schools"
Showing
81
-
100
of
112
Search:
''
,
query time: 0.02s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
81
Pharmacoeconomic review report: Sarilumab (Kevzara)
Published 2017
CADTH
Read Now
82
Pharmacoeconomic report: Satralizumab (Enspryng) : (Hoffmann-La Roche Limited) : indication : neuromyelitis optica spectrum disorder
Published 2021
Canadian Agency for Drugs and Technologies in Health
Read Now
83
CADTH reimbursement recommendation: Satralizumab (Enspryng) : for the treatment of neuromyelitis optica spectrum disorder : recommendation : reimburse with conditions
Published 2021
Canadian Agency for Drugs and Technologies in Health
Read Now
84
Clinical review report: Tildrakizumab (Ilumya) : (Sun Pharma Global FZE) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candida...
Published 2021
Canadian Agency for Drugs and Technologies in Health
Read Now
85
CADTH reimbursement recommendation: Tildrakizumab (Ilumya) : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or...
Published 2021
Canadian Agency for Drugs and Technologies in Health
Read Now
86
Pharmacoeconomic review report: Tildrakizumab (Ilumya) : (Sun Pharma Global FZE) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are...
Published 2021
Canadian Agency for Drugs and Technologies in Health
Read Now
87
Third-line drugs for type 2 diabetes -- project protocol
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
88
Entyvio (Vedolizumab)
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
89
Storage, handling, and administration of expressed human breast milk : a review of guidelines
Published 2016
Canadian Agency for Drugs and Technologies in Health
Read Now
90
Idarucizumab for reversing anticoagulation in adults treated with dabigatran : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2017
Canadian Agency for Drugs and Technologies in Health
Read Now
91
Omalizumab treatment for adults and children with allergic asthma : a review of the clinical effectiveness, cost-effectiveness, and guidelines
Published 2015
Canadian Agency for Drugs and Technologies in Health
Read Now
92
Human growth hormone treatment for Prader-Willi syndrome in adolescent and adult patients: clinical evidence, safety, and guidelines
Published 2015
CADTH Rapid Response Service
Read Now
93
Long-term use of ranibizumab for the treatment of age-related macular degeneration : a review of the clinical and cost-effectiveness and guidelines
Published 2014
Canadian Agency for Drugs and Technologies in Health
Read Now
94
Tocilizumab (Actemra, intravenous) : for the treatment of signs and symptoms of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have r...
Published 2014
Canadian Agency for Drugs and Technologies in Health
Read Now
95
HPV testing for primary cervical cancer screening : recommendations report
Published 2019
CADTH
Read Now
96
High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines
by
Wells, Charlotte
,
Grobelna, Aleksandra
Published 2019
CADTH
Read Now
97
HPV testing for primary cervical cancer screening : a health technology assessment
by
Chao, Yi-Sheng
Published 2019
Canadian Agency for Drugs and Technologies in Health
Read Now
98
Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : treatment of adult patients with active psoriatic arthritis who have responded inadequatel...
Published 2018
Canadian Agency for Drugs and Technologies in Health
Read Now
99
Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
Published 2018
Canadian Agency for Drugs and Technologies in Health
Read Now
100
Non-invasive methods for diagnosis and monitoring of liver fibrosis in patients with chronic hepatitis B and C : a review of diagnostic accuracy, clinical effectiveness, cost-effec...
Published 2015
Canadian Agency for Drugs and Technologies in Health
1
2
3
4
5
6
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Classification: 140 - Specific philosophical schools
Year of Publication
From:
To:
Classification
140 - Specific philosophical schools
610 - Medicine & health
40
330 - Economics
30
700 - The arts; fine & decorative arts
21
Language
English
112
Collection
National Center for Biotechnology Information
112
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
19
Canadian Agency for Drugs and Technologies in Health Rapid Response Service
12
Chao, Yi-Sheng
3
Spry, Carolyn
3
Adcock, Lorna
2
more ...
Argáez, Charlene
2
Campbell, Kaitryn
2
Edge, Rob
2
Gray, Casey
2
Grobelna, Aleksandra
2
La Fleur, Philip
2
Marchand, Dave K.
2
Multiple Sclerosis Society of Canada
2
Picheca, Lory
2
Seal, Kelsey
2
Wells, Charlotte
2
Williams, D.
2
Young, Calvin
2
see all ...
less ...
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?page=5&filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=dewey-ones%3A%22140+-+Specific+philosophical+schools%22&type=AllFields
Send by Email
×
Loading...